Videos

Expert Cmdr. Jennifer Lind, PharmD, MPH, MBA, discussed how her work in the CDC and the USPHS is a unique path for pharmacists interested in public health.

Sheila Plasencia, director of practice support at the Community Oncology Alliance, discussed COA’s new tool to help practices prepare for the Enhancing Oncology Model.

Nick Ferreyros, managing director of policy, advocacy, and communications at the Community Oncology Alliance, discussed the Alliance’s efforts surrounding PBMs and 340B reform.

Kandy Dunnigan, AAS, CPhT-Adv, a drug diversion analyst at Novant Health, discusses her role in the pharmacy.

In his closing thoughts, Dr Haumschild discusses unmet needs in the treatment landscape for ovarian cancer.

A medical expert navigates clinical pathway considerations in the treatment of ovarian cancer.

Indya Wilson, a pharmacy education support specialist at Novant Health Pharmacy Administration, discusses her role in the pharmacy and the benefits of alternative career paths for pharmacy technicians.

Following this year’s Match Day on March 15, pharmacists at US Pharmacopeia (USP) explain some of the opportunities student pharmacists can pursue outside of the traditional pharmacy career model.

Trastuzumab deruxtecan was approved by the FDA for HER2-low breast cancer treatment in 2022 and could also benefit some patients with hormone receptor-positive or triple-negative disease.

This episode features Bruce Berger, PhD, president of Berger Consulting, LLC, who discusses how pharmacists should best use motivational interviewing with patients.

Hannah Nivens, CPhT, a pharmacy distribution specialist at Novant Health Pharmacy Administration, discusses pharmacy distribution for pharmacy technicians.

Experts discuss novel agents being evaluated for use as third-line treatment options and provide their closing thoughts on this discussion.

Brandon Dyson, PharmD, BCOP, BCPS, explores considerations when selecting the next line of treatment, and the efficacy of omacetaxine and ponatinib as third-line therapy options.

Emily Graham, PharmD, MS, BCOP, an Oncology Clinical Pharmacy Specialist at Allegheny Health Network in Pittsburg, Pennsylvania, discusses the potential outcomes of mirvetuximab for patients with platinum-resistant ovarian cancer.

Quality of life and safety profiles are discussed by Ryan Haumschild, PharmD, MS, MBA.

Dr Haumschild navigates financial considerations associated with treatment of ovarian cancer.

In part 2 of this panel discussion, experts discuss how they define traditional versus nontraditional oncology pharmacy roles and where roles within industry fit in.

Following the release of new guidelines on childhood obesity, some experts raised concerns about the safety of using anti-obesity drugs in young people.

Pharmacy departments can be one of the most expensive departments in a cancer center practice, but the revenue generated for its services typically far outpaces associated costs.

AI-enabled algorithms can also augment clinical decision making for health care professionals using real-time data analysis and decision support to treat patients more efficiently and accurately.

John E. Clark, PharmD, MS, FASHP, FFSHP, Director, Diversity, Equity, and Inclusion at the Taneja College of Pharmacy, University of South Florida, discusses the importance of addressing social determinants of health to improve patient outcomes.

Through automated tools related to scheduling, prior authorization, and radiation planning tasks, there are efforts to shorten the time from diagnosis to treatment to improve patient outcomes.

Deep learning AI models like ChatGPT health care edition, coupled with applications targeting pain points in practice workflow, present a very exciting vision for the future.

Sheldon Litwin, MD, a cardiologist at the Medical University of South Carolina, discussed the significant recent advances in anti-obesity drugs.

Pharmacy technicians and pharmacy technician leadership from UPMC Presbyterian discuss the importance of diverse representation.

Pharmacy technicians and pharmacy technician leadership from UPMC Presbyterian discuss what being a Black health care workers means to them.

Donna Ryan, MD, discussed her presentation about pharmacological approaches for obesity, which patients they are indicated for, and considerations for pharmacists.

Neal Dave, PharmD, reviews the therapeutic options considered for patients with a T315I mutation identified during mutational analysis.

Brandon Dyson, PharmD, BCOP, BCPS, reviews the challenges in treatment of resistant chronic myeloid leukemia and Philadelphia chromosome-positive ALL.

Although scientists have long been working on anti-obesity medications, several key failures in recent decades have made this a challenge.